Ing Groep Nv Seagen Inc. Transaction History

Ing Groep Nv

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$191.51 - $216.16 $2.33 Million - $2.63 Million	-12,175 Reduced 15.32%	67,298 $14.3 Million
Q2 2023 Aug 07, 2023	BUY	$187.64 - $206.25 $12.7 Million - $13.9 Million	67,572 Added 567.78%	79,473 $15.3 Million
Q1 2023 May 09, 2023	SELL	$127.59 - $203.08 $622,001 - $990,015	-4,875 Reduced 29.06%	11,901 $2.41 Million
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $295,185 - $350,012	2,515 Added 17.64%	16,776 $2.16 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $1.93 Million - $2.57 Million	14,261 New	14,261 $1.95 Million
Q2 2022 Aug 08, 2022	SELL	$108.81 - $179.33 $225,019 - $370,854	-2,068 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $681,777 - $899,745	-5,700 Reduced 73.38%	2,068 $298,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $650,974 - $871,466	4,566 Added 142.6%	7,768 $1.2 Million
Q3 2021 Nov 02, 2021	BUY	$142.45 - $169.82 $284 - $339	2 Added 0.06%	3,202 $544,000
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $432,256 - $515,520	3,200 New	3,200 $505,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

Stay updated on Ing Groep Nv with notifications on news.